Amphastar Pharmaceuticals is a healthcare company specializing in the development, manufacturing, and marketing of injectable and inhalation pharmaceuticals. Its core products include generic and proprietary drugs, particularly in the areas of anesthetics, anti-infectives, and specialty pharmaceuticals. The company operates primarily in the injectable segment, which is a significant revenue source, alongside its focus on inhalation products. Amphastar's business model is centered on innovation and regulatory compliance to meet market needs.
The investment profile of Amphastar Pharmaceuticals is more aligned with value investors, given its current market position and financial metrics. The company has shown volatility in revenue, which may appeal to those seeking potential recovery opportunities. However, the lack of dividends and recent performance trends suggest a cautious approach. Investors may consider a medium to long-term horizon for potential stabilization and growth.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-19 | Hold | Buy | Strong EPS growth and positive momentum indicators. |
| 2026-08-08 | Sell | Hold | Weak fundamentals and high risk offset recent momentum. |
| 2026-07-23 | — | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-18 | Barclays | Target Raised | 20 → 23 | 21.3694 |
| 2026-06-03 | Barclays | Target Lowered | 23 → 20 | 18.45 |
| 2026-05-14 | Wells Fargo | Rating Downgraded | — → 19 | 18.32 |
| 2026-05-11 | Piper Sandler | Target Lowered | 25 → 21 | 19 |
| 2026-04-20 | Jefferies | Rating Downgraded | — → 22 | 22.92 |
| 2025-12-08 | Barclays | Update | — → 30 | 26.01 |
